Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43884   clinical trials with a EudraCT protocol, of which   7296   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Prevention of breast cancer-related lymphedema with tacrolimus

    Summary
    EudraCT number
    2018-003416-50
    Trial protocol
    DK  
    Global end of trial date
    22 Nov 2022

    Results information
    Results version number
    v1(current)
    This version publication date
    21 Oct 2023
    First version publication date
    21 Oct 2023
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    2018-BCRL-TACRO
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04390685
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Odense university Hospital
    Sponsor organisation address
    J.B. Winsløws vej 4, Odense, Denmark, 5000
    Public contact
    Dept. of Plastic Surgery, Odense University Hospital, 0045 65412436 , jens.sorensen@rsyd.dk
    Scientific contact
    Dept. of Plastic Surgery, Odense University Hospital, 0045 65412436 , jens.sorensen@rsyd.dk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Interim
    Date of interim/final analysis
    28 Sep 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    22 Nov 2022
    Global end of trial reached?
    Yes
    Global end of trial date
    22 Nov 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The study will evaluate the feasibility of tacrolimus ointment in preventing lymphedema after breast cancer treatment.
    Protection of trial subjects
    The protection of clinical trial subjects is consistent with the principles set out in the Declaration of Helsinki
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    29 Feb 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Denmark: 61
    Worldwide total number of subjects
    61
    EEA total number of subjects
    61
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    49
    From 65 to 84 years
    12
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Participants were recruited at Odense University Hospital, Lillebælt Hospital Vejle, and Hospital of Southwest Jutland in Esbjerg from February 2020 to June 2022. Patients included at Odense University hospital were assigned to the treatment group, and patients included at Vejle and Esbjerg were allocated to the control group.

    Pre-assignment
    Screening details
    Inclusion took place 1-4 days prior to the scheduled axillary lymph node dissection surgery. During the course of breast cancer treatment, potential participants were screened for eligibility criteria at the outpatient clinic for each participating study site by clinical staff.

    Period 1
    Period 1 title
    Overall period
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Invervention
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    Tacrolimus (0.1 % tacrolimus)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Ointment
    Routes of administration
    Cutaneous use
    Dosage and administration details
    1 thin layer on the axilla, arm and hand daily for 12 months

    Arm title
    Control
    Arm description
    Control group not recieving any treatment
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 1
    Invervention Control
    Started
    22
    39
    3 months
    19
    38
    6 months
    19
    39
    9 months
    19
    37
    12 months
    18
    37
    Completed
    18
    37
    Not completed
    4
    2
         Consent withdrawn by subject
    3
    -
         Lost to follow-up
    1
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall period
    Reporting group description
    -

    Reporting group values
    Overall period Total
    Number of subjects
    61 61
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    11 11
        From 65-84 years
    50 50
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    53.89 ± 10.60 -
    Gender categorical
    Units: Subjects
        Female
    61 61
        Male
    0 0
    Body mass index
    Units: kg/m^2
        arithmetic mean (standard deviation)
    26.49 ± 4.70 -

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Invervention
    Reporting group description
    -

    Reporting group title
    Control
    Reporting group description
    Control group not recieving any treatment

    Subject analysis set title
    Endpoints
    Subject analysis set type
    Per protocol
    Subject analysis set description
    Data was analyzed per protocol.

    Primary: Lymphedema diagnosis

    Close Top of page
    End point title
    Lymphedema diagnosis
    End point description
    End point type
    Primary
    End point timeframe
    Observed at 12 months follow up
    End point values
    Invervention Control
    Number of subjects analysed
    18
    37
    Units: subjects
        Yes
    7
    13
        No
    11
    24
    Statistical analysis title
    Paired t-test
    Comparison groups
    Invervention v Control
    Number of subjects included in analysis
    55
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    > 0.05
    Method
    t-test, 2-sided
    Confidence interval

    Secondary: Lymphedema criteria met?

    Close Top of page
    End point title
    Lymphedema criteria met?
    End point description
    Was a change of a least 10% seen in the arm at-risk
    End point type
    Secondary
    End point timeframe
    baseline to 12 months
    End point values
    Invervention Control
    Number of subjects analysed
    18
    37
    Units: subjects
        Yes
    3
    4
        No
    15
    33
    Statistical analysis title
    Paired t-test
    Comparison groups
    Invervention v Control
    Number of subjects included in analysis
    55
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    > 0.05
    Method
    t-test, 2-sided
    Confidence interval

    Secondary: Change in arm volume difference

    Close Top of page
    End point title
    Change in arm volume difference
    End point description
    Change in difference in arm volume for each patient fra baseline to 12 months
    End point type
    Secondary
    End point timeframe
    Baseline to 12 months
    End point values
    Invervention Control
    Number of subjects analysed
    18
    37
    Units: millilitre(s)
        arithmetic mean (standard deviation)
    95.22 ± 34.93
    76.26 ± 24.18
    Statistical analysis title
    Paired t-test
    Comparison groups
    Invervention v Control
    Number of subjects included in analysis
    55
    Analysis specification
    Pre-specified
    Analysis type
    equivalence
    P-value
    > 0.05
    Method
    t-test, 2-sided
    Confidence interval

    Secondary: LYMPH ICF

    Close Top of page
    End point title
    LYMPH ICF
    End point description
    Change in LYMPH ICF scores
    End point type
    Secondary
    End point timeframe
    baseline to 12 months
    End point values
    Invervention Control
    Number of subjects analysed
    18
    37
    Units: Arbitary unit
        arithmetic mean (standard deviation)
    5.14 ± 3.40
    10.80 ± 2.37
    Statistical analysis title
    Paired t-test
    Comparison groups
    Invervention v Control
    Number of subjects included in analysis
    55
    Analysis specification
    Pre-specified
    Analysis type
    equivalence
    P-value
    > 0.05
    Method
    t-test, 2-sided
    Confidence interval

    Secondary: DASH

    Close Top of page
    End point title
    DASH
    End point description
    change in DASH scores
    End point type
    Secondary
    End point timeframe
    Baseline to 12 months
    End point values
    Invervention Control
    Number of subjects analysed
    18
    37
    Units: Arbitary unit
        arithmetic mean (standard deviation)
    8.51 ± 2.18
    7.41 ± 1.53
    Statistical analysis title
    Paired t-test
    Comparison groups
    Invervention v Control
    Number of subjects included in analysis
    55
    Analysis specification
    Pre-specified
    Analysis type
    equivalence
    P-value
    > 0.05
    Method
    t-test, 2-sided
    Confidence interval

    Secondary: L-Dex

    Close Top of page
    End point title
    L-Dex [1]
    End point description
    Any assessed for the intervention group
    End point type
    Secondary
    End point timeframe
    baseline to 12 months
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only the intervention group was assessed with l-dex
    End point values
    Invervention
    Number of subjects analysed
    18
    Units: Arbitary unit
        arithmetic mean (standard deviation)
    5.98 ± 2.51
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    0-12 months
    Adverse event reporting additional description
    Data collected throughout the study
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    none
    Dictionary version
    0
    Reporting groups
    Reporting group title
    intervention
    Reporting group description
    The intervention group was instructed to apply a thin layer of 0.1% tacrolimus ointment to the arm, hand, and axilla for a period. of 12 months starting from the day after surgery.

    Serious adverse events
    intervention
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 22 (0.00%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    intervention
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    5 / 22 (22.73%)
    Skin and subcutaneous tissue disorders
    Flushing
    Additional description: In relation to alcohol intake
         subjects affected / exposed
    2 / 22 (9.09%)
         occurrences all number
    2
    Folliculitis
         subjects affected / exposed
    2 / 22 (9.09%)
         occurrences all number
    2
    Infection
    Additional description: postoperative skin infection in the axilla
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA